Cargando…

P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

Detalles Bibliográficos
Autores principales:	Cheah, C. Y., Bartlett, N. L., Assouline, S., Schuster, S. J., Seog Kim, W., Shadman, M., Isufi, I., Yin, S., Doral, M. Y., Sit, J., Chen, V., Huang, H., Zhou, M., Wei, M. C., Budde, L. E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429007/ http://dx.doi.org/10.1097/01.HS9.0000847364.49527.45

Ejemplares similares

Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
por: Bartlett, Nancy L., et al.
Publicado: (2023)

Targeted Treatment of Relapsed or Refractory Follicular Lymphoma: Focus on the Therapeutic Potential of Mosunetuzumab
por: Lopedote, Paolo, et al.
Publicado: (2023)

P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY
por: Sehn, Laurie H., et al.
Publicado: (2023)

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
por: Budde, Lihua E., et al.
Publicado: (2022)

P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF A PIVOTAL PHASE II STUDY
por: Matasar, M., et al.
Publicado: (2022)

Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma
por: Munakata, Wataru, et al.
Publicado: (2023)

P1125: CELESTIMO: A PHASE III TRIAL EVALUATING THE EFFICACY AND SAFETY OF MOSUNETUZUMAB PLUS LENALIDOMIDE VERSUS RITUXIMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
por: Nastoupil, L., et al.
Publicado: (2022)

Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting
por: Cao, Yang, et al.
Publicado: (2023)

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Clinical characteristics of 1124 children with epiphyseal fractures
por: Deng, Hansheng, et al.
Publicado: (2023)

P060: Prognosis of patients with relapsed and refractory classic Hodgkin lymphoma after nivolumab discontinuation and efficacy of nivolumab retreatment
por: Fedorova, Liudmila, et al.
Publicado: (2022)

P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY
por: Mehta-Shah, Neha, et al.
Publicado: (2023)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Validation of the juvenile artritis disease activity score in 1124 patient visits
por: de Vries, LD, et al.
Publicado: (2011)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
por: Ahn, Jae-Sook, et al.
Publicado: (2014)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
por: Cerchione, Claudio, et al.
Publicado: (2016)

Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice
por: Hulin, Cyrille, et al.
Publicado: (2018)

Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study
por: Olszewski, Adam J., et al.
Publicado: (2023)

The Southern Retreat, Thomas Hodgkin, and Achille-Louis Foville.
por: Cherry, C L
Publicado: (1979)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

1124. Increasing Student Confidence in Antimicrobial Prescribing with a Novel Teaching Framework
por: Sheffield, Virginia, et al.
Publicado: (2020)

Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience
por: Somers, Katherine M., et al.
Publicado: (2023)

Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
por: Voorhees, Timothy J, et al.
Publicado: (2020)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

PB2063: CHARACTERISTICS AND THERAPEUTIC RESULTS OF PATIENTS WITH REFRACTORY/RELAPSED HODGKIN LYMPHOMA IN A TUNISIAN CENTER
por: Kammoun, F., et al.
Publicado: (2022)

Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma
por: Evens, Andrew M., et al.
Publicado: (2022)

ESHAP salvage therapy for relapsed or refractory non-Hodgkin's lymphoma.
por: Choi, Chul Won, et al.
Publicado: (2002)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014)

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review
por: Fedele, Roberta, et al.
Publicado: (2015)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
por: Hallam, Simon
Publicado: (2018)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
por: Younes, Anas, et al.
Publicado: (2017)

Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas
por: Kim, Seok-Jin, et al.
Publicado: (2019)

1124. Impact of a Best Practice Advisory for Pediatric Patients with Staphylococcus aureus Bloodstream Infection
por: Lloyd, Elizabeth C, et al.
Publicado: (2019)

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2021)

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia
por: Yang, Qing-Ming, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_33duactuult4gdts226275frio